Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 7,362 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NERVES Clear all
Terminated No phase listed Observational

Prognosis and Therapeutic Biomarkers for Glioblastoma Patients

NCT03403803
View directory record Official record
Conditions
Glioblastoma
Interventions
Optune
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 28, 2026, 3:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

NCT03958383
View directory record Official record
Conditions
Melanoma
Interventions
hu14.18-IL2, Radiation Therapy, Nivolumab, Ipilimumab
Biological · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Not applicable Interventional Results available

A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache

NCT00203294
View directory record Official record
Conditions
Migraine
Interventions
lidocaine, bupivicaine and saline, lidocaine plus bupivicaine plus triamcinolone (steroid)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 28, 2026, 3:55 AM EDT
Terminated Phase 2 Interventional Results available

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

NCT03295396
View directory record Official record
Conditions
Glioma
Interventions
Dordaviprone (ONC201)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
San Francisco, California • Stanford, California • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 28, 2026, 3:55 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.

NCT02176642
View directory record Official record
Conditions
Urinary Urge Incontinence
Interventions
Oxybutynin extended release, Posterior Tibial Nerve Stimulation, Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

NCT06090266
View directory record Official record
Conditions
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
Interventions
OR502, Cemiplimab
Drug
Lead sponsor
OncoResponse, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

NCT04552223
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Jose Lutzky, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma

NCT00683761
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma, Oligodendroglioma
Interventions
131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2009 · Synced Oct 28, 2026, 3:55 AM EDT
Completed No phase listed Observational

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

NCT03696069
View directory record Official record
Conditions
Melanoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 2 Interventional

Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate

NCT03234361
View directory record Official record
Conditions
Hypertension
Interventions
High Phosphate Phase, Low Phosphate Phase
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 28, 2026, 3:55 AM EDT
Active, not recruiting Phase 1 Interventional

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

NCT04930783
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
CDX-301, NEOVAX, Nivolumab, Pembrolizumab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

IINB vs. QLB for Elective Open Inguinal Herniorrhaphy

NCT03007966
View directory record Official record
Conditions
Nerve Block, Herniorrhaphy, Regional Anesthesia
Interventions
Ilioinguinal / Iliohypogastric Block, Quadratus Lumborum Block, Bupivacaine 0.25%, Epinephrine 1:200k, Clonidine 1.66mcg/cc
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Early Phase 1 Interventional

Intercostobrachial Nerve Block (ICBN) for Tourniquet Pain: Is it Necessary?

NCT03797924
View directory record Official record
Conditions
Nerve Block, Pain
Interventions
Receive ICBN with ropivacaine, No ICBN block
Drug · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 28, 2026, 3:55 AM EDT
Not listed No phase listed Observational

GI Complications in Cancer Immunotherapy Patients

NCT02784366
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 28, 2026, 3:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

NCT01483820
View directory record Official record
Conditions
Neuroblastoma, Medulloblastoma
Interventions
TPI 287
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
12 Months to 30 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
San Diego, California • Hartford, Connecticut • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma

NCT00002569
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
lomustine, procarbazine hydrochloride, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2018
U.S. locations
95
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 28, 2026, 3:55 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

NCT04291105
View directory record Official record
Conditions
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Interventions
VV1, Cemiplimab
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

NCT03871257
View directory record Official record
Conditions
Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
Interventions
Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
125
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

NCT00483301
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Sorafenib (BAY 43-9006), ABI-007(Abraxane)
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California • Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 28, 2026, 3:55 AM EDT
Terminated Not applicable Interventional Results available

Preemptive Femoral & Lateral Femoral Cutaneous Nerve Blocks for THA Acute Pain

NCT01997567
View directory record Official record
Conditions
Internal Derangement of Hip, Acetabular Labrum Tear
Interventions
Ropivacaine, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 28, 2026, 3:55 AM EDT
Not yet recruiting Phase 2 Interventional

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

NCT07511036
View directory record Official record
Conditions
Melanoma
Interventions
Cemiplimab, Lpilimumab, Fianlimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Not applicable Interventional

Coolief Cooled Radiofrequency vs. Conventional Radiofrequency to Manage OA Knee Pain

NCT04145011
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Cooled Radiofrequency, Standard Radiofrequency
Device
Lead sponsor
Avanos Medical
Other
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Altoona, Pennsylvania • Sewickley, Pennsylvania • State College, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Not applicable Interventional

Comparing Femoral Nerve Catheters to Single Shot Femoral Nerve Blocks for Total Knee Replacement Surgery

NCT02106481
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Femoral Nerve Catheters, Single Shot Femoral Nerve Blocks
Drug
Lead sponsor
Eastern Maine Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 28, 2026, 3:55 AM EDT